All the news articles and press releases in one place.


Date / Time Source Company % Chg Sector Market Cap Announcement
13Sep19 07:00 RNS-R Angle 5.19% Industrial Equipment, Goods & Services £116.2m Use of Parsortix in head and neck cancer
10Sep19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Research with Parsortix in prostate cancer
04Sep19 07:00 RNS-R Angle 5.19% Industrial Equipment, Goods & Services £116.2m Parsortix for Neuroendocrine Analysis in SCLC
29Aug19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Initiation of Ovarian Cancer Study
31Jul19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Prelim Results for the year ended 30 April 2019
22Jul19 07:00 RNS-R Angle 5.19% Industrial Equipment, Goods & Services £116.2m Use of Parsortix for single cell analysis of CTCs
16Jul19 09:19 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Holding(s) in Company
12Jul19 10:22 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Result of General Meeting anf Total Voting Rights
28Jun19 13:37 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Notice of Preliminary Results and Webcast
28Jun19 13:08 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Holding(s) in Company
25Jun19 17:19 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Result of Placing
25Jun19 08:02 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Accelerated bookbuild to raise £18.0m
21Jun19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Parsortix used to investigate immunotherapy target
05Jun19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Completion of Ovarian Cancer Pre-Study
31May19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Positive Results from FDA Clinical Study
26Apr19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m IMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18Apr19 07:00 RNS-R Angle 5.19% Industrial Equipment, Goods & Services £116.2m Parsortix used in new cancer assessment technique
12Apr19 07:00 RNS-R Angle 5.19% Industrial Equipment, Goods & Services £116.2m LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
04Apr19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m AACR 2019
11Mar19 07:00 RNS Legal & General Group -1.13% Various Various Holding(s) in Company
07Mar19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m ENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28Feb19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25Feb19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11Feb19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Research into role of immune cells in cancer
31Jan19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Interim Results
29Jan19 07:00 RNS-R Angle 5.19% Industrial Equipment, Goods & Services £116.2m NEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11Jan19 14:05 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Second Price Monitoring Extn
11Jan19 14:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Price Monitoring Extension
11Jan19 11:05 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Second Price Monitoring Extn
11Jan19 11:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Price Monitoring Extension
11Jan19 09:05 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Second Price Monitoring Extn
11Jan19 09:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Price Monitoring Extension
10Jan19 16:41 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Second Price Monitoring Extn
10Jan19 16:36 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Price Monitoring Extension
10Jan19 16:01 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m BREAKTHROUGH CANCER RESEARCH USING PARSORTIX
09Jan19 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Notice of Results
21Dec18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Issue of LTIP Options and Share Options
28Nov18 07:00 RNS-R Angle 5.19% Industrial Equipment, Goods & Services £116.2m LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13Nov18 17:10 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Holding(s) in Company
05Nov18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Acquisition of outstanding shares
02Nov18 14:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Price Monitoring Extension
01Nov18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Appointment of Dr Jan Groen as NED
30Oct18 16:21 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Result of AGM
29Oct18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25Oct18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Good Progress with FDA Studies
09Oct18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Notice of AGM
25Jul18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Preliminary Results for year ended 30 April 2018
24Jul18 17:42 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m EIS/VCT Advance Assurance and Total Voting Rights
18Jul18 10:34 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Result of General Meeting
02Jul18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Notice of Preliminary Results
25Jun18 18:20 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Results of Fundraising
25Jun18 14:58 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Close of Accelerated Bookbuild
25Jun18 07:50 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Proposed Placing of New Ordinary Shares
04Jun18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m ENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
19Apr18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Breakthrough Research with Parsortix
05Apr18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m First patient enrolled in FDA study
26Mar18 16:35 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Price Monitoring Extension
26Mar18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Research Update
06Feb18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m ANGLE plc: RESEARCH GRANT FROM ABBOTT
31Jan18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Interim Results
10Jan18 10:16 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Notice of Results
08Jan18 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m ANGLE plc:Prostate cancer ARV7 treatment biomarker
27Dec17 11:49 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Holding(s) in Company
12Dec17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Transfer of Lock-in Shares
08Dec17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m PARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
23Nov17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m PHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17Nov17 16:06 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Holding(s) in Company
06Nov17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Holding(s) in Company
06Nov17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Holding(s) in Company
06Nov17 07:00 RNS Legal & General Group -1.13% Various Various Holding(s) in Company
02Nov17 10:04 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Holding(s) in Company
01Nov17 08:12 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m ANGLE: Completion of Fundraising and Acquisition
31Oct17 14:18 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Result of AGM
30Oct17 10:31 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Result of General Meeting
23Oct17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Parsortix harvests cancer cells from bone marrow
20Oct17 15:05 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Notice of AGM
12Oct17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Proposed further subscription for £2.8 million
09Oct17 07:02 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m CTCs harvested with Parsortix grown in laboratory
09Oct17 07:01 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Potential new analytical protocol using Parsortix
05Oct17 11:46 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Results of Fundraising
05Oct17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Acquisition and Fundraising
13Sep17 17:36 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Holding(s) in Company
13Sep17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Exclusive worldwide option over megakaryocyte IP
11Sep17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Co-Marketing Partnership with QIAGEN
05Sep17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Change of Adviser
27Jul17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Preliminary Results
06Jul17 10:05 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Notice of Results
04Jul17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Successful Headline Data in Ovarian Cancer Studies
15Jun17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Parsortix breakthrough in prostate cancer
03May17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Business Update
04Apr17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Holding(s) in Company
03Apr17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Parsortix enables analysis in head and neck cancer
30Mar17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Prostate Cancer Update
14Feb17 11:39 EQS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Edison issues outlook on Angle
26Jan17 07:01 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Interim Evaluation of Ovarian Cancer Study
26Jan17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Interim Results
04Jan17 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Notice of Results
28Nov16 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m ISSUE OF SHARE OPTIONS
24Nov16 14:48 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Result of GM
04Nov16 07:00 RNS Angle 5.19% Industrial Equipment, Goods & Services £116.2m Barts Research Supports Potential Use of Parsortix
Date / Time Source Company % Chg
13Sep19 07:00 RNS-R Angle 5.19%
Use of Parsortix in head and neck cancer
10Sep19 07:00 RNS Angle 5.19%
Research with Parsortix in prostate cancer
04Sep19 07:00 RNS-R Angle 5.19%
Parsortix for Neuroendocrine Analysis in SCLC
29Aug19 07:00 RNS Angle 5.19%
Initiation of Ovarian Cancer Study
31Jul19 07:00 RNS Angle 5.19%
Prelim Results for the year ended 30 April 2019
22Jul19 07:00 RNS-R Angle 5.19%
Use of Parsortix for single cell analysis of CTCs
16Jul19 09:19 RNS Angle 5.19%
Holding(s) in Company
12Jul19 10:22 RNS Angle 5.19%
Result of General Meeting anf Total Voting Rights
28Jun19 13:37 RNS Angle 5.19%
Notice of Preliminary Results and Webcast
28Jun19 13:08 RNS Angle 5.19%
Holding(s) in Company
25Jun19 17:19 RNS Angle 5.19%
Result of Placing
25Jun19 08:02 RNS Angle 5.19%
Accelerated bookbuild to raise £18.0m
21Jun19 07:00 RNS Angle 5.19%
Parsortix used to investigate immunotherapy target
05Jun19 07:00 RNS Angle 5.19%
Completion of Ovarian Cancer Pre-Study
31May19 07:00 RNS Angle 5.19%
Positive Results from FDA Clinical Study
26Apr19 07:00 RNS Angle 5.19%
IMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18Apr19 07:00 RNS-R Angle 5.19%
Parsortix used in new cancer assessment technique
12Apr19 07:00 RNS-R Angle 5.19%
LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
04Apr19 07:00 RNS Angle 5.19%
AACR 2019
11Mar19 07:00 RNS Legal & General Group -1.13%
Holding(s) in Company
07Mar19 07:00 RNS Angle 5.19%
ENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28Feb19 07:00 RNS Angle 5.19%
FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25Feb19 07:00 RNS Angle 5.19%
CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11Feb19 07:00 RNS Angle 5.19%
Research into role of immune cells in cancer
31Jan19 07:00 RNS Angle 5.19%
Interim Results
29Jan19 07:00 RNS-R Angle 5.19%
NEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11Jan19 14:05 RNS Angle 5.19%
Second Price Monitoring Extn
11Jan19 14:00 RNS Angle 5.19%
Price Monitoring Extension
11Jan19 11:05 RNS Angle 5.19%
Second Price Monitoring Extn
11Jan19 11:00 RNS Angle 5.19%
Price Monitoring Extension
11Jan19 09:05 RNS Angle 5.19%
Second Price Monitoring Extn
11Jan19 09:00 RNS Angle 5.19%
Price Monitoring Extension
10Jan19 16:41 RNS Angle 5.19%
Second Price Monitoring Extn
10Jan19 16:36 RNS Angle 5.19%
Price Monitoring Extension
10Jan19 16:01 RNS Angle 5.19%
BREAKTHROUGH CANCER RESEARCH USING PARSORTIX
09Jan19 07:00 RNS Angle 5.19%
Notice of Results
21Dec18 07:00 RNS Angle 5.19%
Issue of LTIP Options and Share Options
28Nov18 07:00 RNS-R Angle 5.19%
LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13Nov18 17:10 RNS Angle 5.19%
Holding(s) in Company
05Nov18 07:00 RNS Angle 5.19%
Acquisition of outstanding shares
02Nov18 14:00 RNS Angle 5.19%
Price Monitoring Extension
01Nov18 07:00 RNS Angle 5.19%
Appointment of Dr Jan Groen as NED
30Oct18 16:21 RNS Angle 5.19%
Result of AGM
29Oct18 07:00 RNS Angle 5.19%
PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25Oct18 07:00 RNS Angle 5.19%
Good Progress with FDA Studies
09Oct18 07:00 RNS Angle 5.19%
Notice of AGM
25Jul18 07:00 RNS Angle 5.19%
Preliminary Results for year ended 30 April 2018
24Jul18 17:42 RNS Angle 5.19%
EIS/VCT Advance Assurance and Total Voting Rights
18Jul18 10:34 RNS Angle 5.19%
Result of General Meeting
02Jul18 07:00 RNS Angle 5.19%
Notice of Preliminary Results
25Jun18 18:20 RNS Angle 5.19%
Results of Fundraising
25Jun18 14:58 RNS Angle 5.19%
Close of Accelerated Bookbuild
25Jun18 07:50 RNS Angle 5.19%
Proposed Placing of New Ordinary Shares
04Jun18 07:00 RNS Angle 5.19%
ENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
19Apr18 07:00 RNS Angle 5.19%
Breakthrough Research with Parsortix
05Apr18 07:00 RNS Angle 5.19%
First patient enrolled in FDA study
26Mar18 16:35 RNS Angle 5.19%
Price Monitoring Extension
26Mar18 07:00 RNS Angle 5.19%
Research Update
06Feb18 07:00 RNS Angle 5.19%
ANGLE plc: RESEARCH GRANT FROM ABBOTT
31Jan18 07:00 RNS Angle 5.19%
Interim Results
10Jan18 10:16 RNS Angle 5.19%
Notice of Results
08Jan18 07:00 RNS Angle 5.19%
ANGLE plc:Prostate cancer ARV7 treatment biomarker
27Dec17 11:49 RNS Angle 5.19%
Holding(s) in Company
12Dec17 07:00 RNS Angle 5.19%
Transfer of Lock-in Shares
08Dec17 07:00 RNS Angle 5.19%
PARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
23Nov17 07:00 RNS Angle 5.19%
PHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17Nov17 16:06 RNS Angle 5.19%
Holding(s) in Company
06Nov17 07:00 RNS Angle 5.19%
Holding(s) in Company
06Nov17 07:00 RNS Angle 5.19%
Holding(s) in Company
06Nov17 07:00 RNS Legal & General Group -1.13%
Holding(s) in Company
02Nov17 10:04 RNS Angle 5.19%
Holding(s) in Company
01Nov17 08:12 RNS Angle 5.19%
ANGLE: Completion of Fundraising and Acquisition
31Oct17 14:18 RNS Angle 5.19%
Result of AGM
30Oct17 10:31 RNS Angle 5.19%
Result of General Meeting
23Oct17 07:00 RNS Angle 5.19%
Parsortix harvests cancer cells from bone marrow
20Oct17 15:05 RNS Angle 5.19%
Notice of AGM
12Oct17 07:00 RNS Angle 5.19%
Proposed further subscription for £2.8 million
09Oct17 07:02 RNS Angle 5.19%
CTCs harvested with Parsortix grown in laboratory
09Oct17 07:01 RNS Angle 5.19%
Potential new analytical protocol using Parsortix
05Oct17 11:46 RNS Angle 5.19%
Results of Fundraising
05Oct17 07:00 RNS Angle 5.19%
Acquisition and Fundraising
13Sep17 17:36 RNS Angle 5.19%
Holding(s) in Company
13Sep17 07:00 RNS Angle 5.19%
Exclusive worldwide option over megakaryocyte IP
11Sep17 07:00 RNS Angle 5.19%
Co-Marketing Partnership with QIAGEN
05Sep17 07:00 RNS Angle 5.19%
Change of Adviser
27Jul17 07:00 RNS Angle 5.19%
Preliminary Results
06Jul17 10:05 RNS Angle 5.19%
Notice of Results
04Jul17 07:00 RNS Angle 5.19%
Successful Headline Data in Ovarian Cancer Studies
15Jun17 07:00 RNS Angle 5.19%
Parsortix breakthrough in prostate cancer
03May17 07:00 RNS Angle 5.19%
Business Update
04Apr17 07:00 RNS Angle 5.19%
Holding(s) in Company
03Apr17 07:00 RNS Angle 5.19%
Parsortix enables analysis in head and neck cancer
30Mar17 07:00 RNS Angle 5.19%
Prostate Cancer Update
14Feb17 11:39 EQS Angle 5.19%
Edison issues outlook on Angle
26Jan17 07:01 RNS Angle 5.19%
Interim Evaluation of Ovarian Cancer Study
26Jan17 07:00 RNS Angle 5.19%
Interim Results
04Jan17 07:00 RNS Angle 5.19%
Notice of Results
28Nov16 07:00 RNS Angle 5.19%
ISSUE OF SHARE OPTIONS
24Nov16 14:48 RNS Angle 5.19%
Result of GM
04Nov16 07:00 RNS Angle 5.19%
Barts Research Supports Potential Use of Parsortix
Date / Time Company % Chg
13Sep19 07:00 Angle 5.19%
Use of Parsortix in head and neck cancer
10Sep19 07:00 Angle 5.19%
Research with Parsortix in prostate cancer
04Sep19 07:00 Angle 5.19%
Parsortix for Neuroendocrine Analysis in SCLC
29Aug19 07:00 Angle 5.19%
Initiation of Ovarian Cancer Study
31Jul19 07:00 Angle 5.19%
Prelim Results for the year ended 30 April 2019
22Jul19 07:00 Angle 5.19%
Use of Parsortix for single cell analysis of CTCs
16Jul19 09:19 Angle 5.19%
Holding(s) in Company
12Jul19 10:22 Angle 5.19%
Result of General Meeting anf Total Voting Rights
28Jun19 13:37 Angle 5.19%
Notice of Preliminary Results and Webcast
28Jun19 13:08 Angle 5.19%
Holding(s) in Company
25Jun19 17:19 Angle 5.19%
Result of Placing
25Jun19 08:02 Angle 5.19%
Accelerated bookbuild to raise £18.0m
21Jun19 07:00 Angle 5.19%
Parsortix used to investigate immunotherapy target
05Jun19 07:00 Angle 5.19%
Completion of Ovarian Cancer Pre-Study
31May19 07:00 Angle 5.19%
Positive Results from FDA Clinical Study
26Apr19 07:00 Angle 5.19%
IMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18Apr19 07:00 Angle 5.19%
Parsortix used in new cancer assessment technique
12Apr19 07:00 Angle 5.19%
LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
04Apr19 07:00 Angle 5.19%
AACR 2019
11Mar19 07:00 AGL LSE,LGEN LSE -1.13%
Holding(s) in Company
07Mar19 07:00 Angle 5.19%
ENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28Feb19 07:00 Angle 5.19%
FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25Feb19 07:00 Angle 5.19%
CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11Feb19 07:00 Angle 5.19%
Research into role of immune cells in cancer
31Jan19 07:00 Angle 5.19%
Interim Results
29Jan19 07:00 Angle 5.19%
NEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11Jan19 14:05 Angle 5.19%
Second Price Monitoring Extn
11Jan19 14:00 Angle 5.19%
Price Monitoring Extension
11Jan19 11:05 Angle 5.19%
Second Price Monitoring Extn
11Jan19 11:00 Angle 5.19%
Price Monitoring Extension
11Jan19 09:05 Angle 5.19%
Second Price Monitoring Extn
11Jan19 09:00 Angle 5.19%
Price Monitoring Extension
10Jan19 16:41 Angle 5.19%
Second Price Monitoring Extn
10Jan19 16:36 Angle 5.19%
Price Monitoring Extension
10Jan19 16:01 Angle 5.19%
BREAKTHROUGH CANCER RESEARCH USING PARSORTIX
09Jan19 07:00 Angle 5.19%
Notice of Results
21Dec18 07:00 Angle 5.19%
Issue of LTIP Options and Share Options
28Nov18 07:00 Angle 5.19%
LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13Nov18 17:10 Angle 5.19%
Holding(s) in Company
05Nov18 07:00 Angle 5.19%
Acquisition of outstanding shares
02Nov18 14:00 Angle 5.19%
Price Monitoring Extension
01Nov18 07:00 Angle 5.19%
Appointment of Dr Jan Groen as NED
30Oct18 16:21 Angle 5.19%
Result of AGM
29Oct18 07:00 Angle 5.19%
PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25Oct18 07:00 Angle 5.19%
Good Progress with FDA Studies
09Oct18 07:00 Angle 5.19%
Notice of AGM
25Jul18 07:00 Angle 5.19%
Preliminary Results for year ended 30 April 2018
24Jul18 17:42 Angle 5.19%
EIS/VCT Advance Assurance and Total Voting Rights
18Jul18 10:34 Angle 5.19%
Result of General Meeting
02Jul18 07:00 Angle 5.19%
Notice of Preliminary Results
25Jun18 18:20 Angle 5.19%
Results of Fundraising
25Jun18 14:58 Angle 5.19%
Close of Accelerated Bookbuild
25Jun18 07:50 Angle 5.19%
Proposed Placing of New Ordinary Shares
04Jun18 07:00 Angle 5.19%
ENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
19Apr18 07:00 Angle 5.19%
Breakthrough Research with Parsortix
05Apr18 07:00 Angle 5.19%
First patient enrolled in FDA study
26Mar18 16:35 Angle 5.19%
Price Monitoring Extension
26Mar18 07:00 Angle 5.19%
Research Update
06Feb18 07:00 Angle 5.19%
ANGLE plc: RESEARCH GRANT FROM ABBOTT
31Jan18 07:00 Angle 5.19%
Interim Results
10Jan18 10:16 Angle 5.19%
Notice of Results
08Jan18 07:00 Angle 5.19%
ANGLE plc:Prostate cancer ARV7 treatment biomarker
27Dec17 11:49 Angle 5.19%
Holding(s) in Company
12Dec17 07:00 Angle 5.19%
Transfer of Lock-in Shares
08Dec17 07:00 Angle 5.19%
PARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
23Nov17 07:00 Angle 5.19%
PHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17Nov17 16:06 Angle 5.19%
Holding(s) in Company
06Nov17 07:00 Angle 5.19%
Holding(s) in Company
06Nov17 07:00 Angle 5.19%
Holding(s) in Company
06Nov17 07:00 AGL LSE,LGEN LSE -1.13%
Holding(s) in Company
02Nov17 10:04 Angle 5.19%
Holding(s) in Company
01Nov17 08:12 Angle 5.19%
ANGLE: Completion of Fundraising and Acquisition
31Oct17 14:18 Angle 5.19%
Result of AGM
30Oct17 10:31 Angle 5.19%
Result of General Meeting
23Oct17 07:00 Angle 5.19%
Parsortix harvests cancer cells from bone marrow
20Oct17 15:05 Angle 5.19%
Notice of AGM
12Oct17 07:00 Angle 5.19%
Proposed further subscription for £2.8 million
09Oct17 07:02 Angle 5.19%
CTCs harvested with Parsortix grown in laboratory
09Oct17 07:01 Angle 5.19%
Potential new analytical protocol using Parsortix
05Oct17 11:46 Angle 5.19%
Results of Fundraising
05Oct17 07:00 Angle 5.19%
Acquisition and Fundraising
13Sep17 17:36 Angle 5.19%
Holding(s) in Company
13Sep17 07:00 Angle 5.19%
Exclusive worldwide option over megakaryocyte IP
11Sep17 07:00 Angle 5.19%
Co-Marketing Partnership with QIAGEN
05Sep17 07:00 Angle 5.19%
Change of Adviser
27Jul17 07:00 Angle 5.19%
Preliminary Results
06Jul17 10:05 Angle 5.19%
Notice of Results
04Jul17 07:00 Angle 5.19%
Successful Headline Data in Ovarian Cancer Studies
15Jun17 07:00 Angle 5.19%
Parsortix breakthrough in prostate cancer
03May17 07:00 Angle 5.19%
Business Update
04Apr17 07:00 Angle 5.19%
Holding(s) in Company
03Apr17 07:00 Angle 5.19%
Parsortix enables analysis in head and neck cancer
30Mar17 07:00 Angle 5.19%
Prostate Cancer Update
14Feb17 11:39 Angle 5.19%
Edison issues outlook on Angle
26Jan17 07:01 Angle 5.19%
Interim Evaluation of Ovarian Cancer Study
26Jan17 07:00 Angle 5.19%
Interim Results
04Jan17 07:00 Angle 5.19%
Notice of Results
28Nov16 07:00 Angle 5.19%
ISSUE OF SHARE OPTIONS
24Nov16 14:48 Angle 5.19%
Result of GM
04Nov16 07:00 Angle 5.19%
Barts Research Supports Potential Use of Parsortix